Exporting Pharmaceuticals: FDA and Trade Rules

Exporting drugs from the United States is governed by two layers of rules: the FDA’s drug-export provisions in the Federal Food, Drug, and Cosmetic Act, and the trade-control rules that apply to almost everything the U.S. ships abroad. Most finished pharmaceuticals are not heavily controlled as dual-use goods — but “lightly controlled” is not “unregulated,” and the rules that govern exporting an unapproved drug are very different from those for an approved one. Here is what actually applies.

The FDA layer: FD&C Act sections 801 and 802

For drugs, the core export rules live in sections 801(e) and 802 of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The path depends on whether the drug is approved for U.S. marketing.

Approved drugs can generally be exported like other regulated products, subject to ordinary labeling and good-manufacturing-practice expectations. The more sensitive question is unapproved drugs — products not (yet) approved for sale in the United States.

Under section 801(e)(1), a drug intended for export is not treated as adulterated or misbranded if it meets the foreign buyer’s specifications, does not conflict with the importing country’s laws, is labeled on the outside of the shipping package as intended for export, and is not sold in U.S. domestic commerce.

Section 802 opens a broader path for exporting certain unapproved drugs — for example, where the product has valid marketing authorization in a “listed” country (a defined set that includes Australia, Canada, Israel, Japan, New Zealand, Switzerland, South Africa, and the EU/EEA) — subject to notification, recordkeeping, and labeling conditions.

FDA export certificates

Importing countries frequently demand proof that a product is legitimately made and marketable in the U.S. The FDA issues export certificates for this purpose, including the Certificate of Pharmaceutical Product (CPP), which follows the World Health Organization format and is used by foreign regulators reviewing a product for their own market authorization. Lining up the right certificate early prevents shipments from stalling at the destination border.

The trade-control layer: EAR, DEA, and sanctions

Separately from the FDA, pharmaceutical exports run through the Export Administration Regulations (EAR), administered by the Bureau of Industry and Security. Most finished drugs classify as EAR99 — subject to the EAR but not requiring a license for most destinations. That status does not switch off compliance: you still cannot ship to an embargoed country or a denied party, and you must screen accordingly. Some active ingredients and precursors with dual-use or chemical-weapons relevance can sit higher on the Commerce Control List.

Two more regulators commonly appear. Controlled substances require authorization from the DEA under the Controlled Substances Import and Export Act — an FDA clearance does not substitute for DEA authorization. And shipments touching sanctioned jurisdictions implicate OFAC programs, which sometimes include humanitarian licensing pathways for medicine but never a blanket exemption you can assume.

A practical compliance sequence

• Confirm approval status. Approved or unapproved? That determines which FD&C Act pathway applies.
• Map the destination’s rules. The importing country’s registration and import requirements often drive the documentation.
• Get the right FDA certificate. Identify whether a CPP or other certificate is needed and apply early.
• Classify under the EAR. Confirm EAR99 or the applicable ECCN; screen all parties and destinations.
• Layer in DEA and OFAC where controlled substances or sanctioned jurisdictions are involved.
• Document everything. Keep complete export and quality records.

For the trade-control mechanics that apply across all exports, see our guides to navigating export compliance for e-commerce and International Trade Law.

Frequently asked questions

Do I need FDA approval to export a drug that isn’t approved in the U.S.? Not necessarily. Sections 801(e) and 802 of the FD&C Act create pathways to export certain unapproved drugs if specific conditions are met — such as the product being authorized in a listed country and the shipment meeting labeling and notification requirements.

What is a Certificate of Pharmaceutical Product? A CPP is an FDA-issued export certificate in the WHO format that foreign regulators use when evaluating a U.S. drug for marketing authorization in their country.

Do most drug exports need a Commerce export license? Most finished pharmaceuticals are EAR99 and need no BIS license for most destinations — but you must still screen the parties and avoid embargoed countries. Controlled substances additionally require DEA authorization.

Can I ship medicine to a sanctioned country? Sometimes, but never assume. OFAC programs may include humanitarian licensing pathways for medicine, but the specific program and any required authorization have to be checked before shipping.

Exporting pharmaceuticals or other regulated goods? Reidel Law Firm provides flat-fee import/export compliance memos covering classification, licensing, and screening — with direct access to the attorney handling your matter. Get a flat-fee import/export compliance memo →